Recent advances in metastatic colorectal cancer (mCRC) are reshaping the treatment landscape for a subgroup of patients with a historically poor prognosis: those with BRAF V600E mutations.

From poor outcomes to targeted strategies

BRAF V600E-mutated mCRC accounts for approximately 8–12% of all metastatic cases and has long been associated with more aggressive disease and limited response to standard chemotherapy. Until recently, treatment options in the first-line setting were largely based on chemotherapy combinations, with targeted approaches reserved for later lines.

This paradigm is now changing.

BREAKWATER: moving targeted therapy to first line

The phase III BREAKWATER study has introduced a new approach by evaluating the combination of encorafenib (BRAF inhibitor) and cetuximab (EGFR inhibitor) together with chemotherapy (mFOLFOX6) in the first-line setting.

The study demonstrated:

• Higher response rates compared to standard-of-care regimens
• Improved progression-free survival
• Emerging evidence of overall survival benefit

These results represent a major shift: for the first time, a biomarker-driven treatment strategy is being used upfront in patients with BRAF V600E-mutated mCRC.

Regulatory landscape: a gap between evidence and access

In the United States, this combination has already been approved in first line, marking a rapid translation of clinical evidence into practice.

In Europe, however, the situation is still evolving. The European Medicines Agency (EMA) is currently reviewing the data for a potential indication extension. As of now, the combination of encorafenib and cetuximab remains approved only for patients who have received prior therapy.

This creates a gap between what is scientifically supported and what is currently accessible to patients across Europe.

ESMO Living Guidelines: already adapting to new evidence

Importantly, the ESMO Living Guidelines for metastatic colorectal cancer have already incorporated the BREAKWATER findings.

They recommend encorafenib + cetuximab + mFOLFOX6 as a first-line treatment option for patients with BRAF V600E-mutated mCRC, reflecting the strength and clinical relevance of the data, while acknowledging that European regulatory approval is still pending.

This highlights the value of living guidelines, which can rapidly integrate emerging evidence and support clinicians in decision-making even before formal regulatory processes are completed.

What this means for patients and health systems

The implications of these developments go beyond a single treatment:

• Early biomarker testing is critical: identifying BRAF status at diagnosis of metastatic disease is essential to guide optimal treatment decisions
• Equity of access remains a challenge: differences in regulatory timelines and reimbursement pathways may delay patient access across countries

Looking ahead

As the EMA evaluation progresses, the oncology community will be closely watching how quickly this new standard can be implemented across Europe.

At Digestive Cancers Europe (DiCE), we remain committed to supporting access to innovative, evidence-based, and patient-centred care, and to ensuring that patients’ perspectives continue to shape the future of cancer treatment.

Learn more about mCRC biomarkers here

Author:

Marianna Vitaloni